All companies have to adapt and evolve over time in order to keep growing and deliver improving returns for their shareholders. However, British Gas brand owner Centrica (LSE: CNA) has rather lurched from one strategy to another since its demerger from British Gas plc in 1997.
I’ve been critical of its erratic history, failure to find a way to deliver sustainable earnings and dividend growth and poor long-term share performance. However, such companies do tend to go through phases where they deliver excellent turnaround returns for value investors, who buy low and sell high.
With Centrica’s shares having this month plumbed depths not seen since last century, could now be the perfect time for value investors to jump in for a recovery?
Waiting game
The market had been told, via a profit warning in November, of a poor performance for 2017. The annual results were released last week and the shares have actually advanced a little in response, as the numbers were only as grim as the market expected. Nevertheless, grim they were. Statutory earnings per share (EPS) plummeted 81% to 6p and even excluding all the nasty stuff, adjusted EPS dropped 25% to 12.6p. The board declared a 12p dividend for the third year running, having reduced the payout in each of the two prior years.
At a current share price of 142p, the trailing price-to-earnings (P/E) ratio is 11.3 on the more favourable adjusted EPS number. The dividend yield is a whopping 8.5%.
Chief executive Iain Conn told investors: “I am determined to restore shareholder value and confidence.” However, with the company continuing to bleed customers and the headwinds from political and regulatory intervention in the energy market, I believe things may well get worse before they get better. If so, the dividend would likely be cut (as some analysts are already forecasting) and the share price could fall further. As such, I’m continuing to avoid the stock at this stage.
Skin in the game
Another potential turnaround prospect beckoning investors is FTSE SmallCap firm Devro (LSE: DVO). This company, which has the long-form description “one of the world’s leading manufacturers of collagen products for the food industry” and the short-form version “sausage skin maker,” released its annual results today.
The first year of Devro’s three-year plan to deliver revenue growth and cost savings across its global operations has progressed well, with the company delivering a top-line advance of 7% thanks to increased volumes. It exceeded its cost reduction target and underlying earnings before interest, tax, depreciation and amortisation (EBITDA) increased 9%.
However, EPS dropped to 12.5p from 13.3p. This was due to higher finance costs, which will begin to fall, because the company has completed major capital investment projects. As it is, strong cash generation in 2017 saw net debt reduce to £135m from £154m and the net debt-to-EBITDA ratio come down to a healthier 2.1 from 2.7.
At a share price of 199p (little changed on the day), Devro’s trailing P/E is 15.9 and its dividend yield is 4.4% on a maintained 8.8p payout. In my view, the business is now well positioned for strong earnings and dividend growth in the coming years and I rate this turnaround stock a ‘buy’.